| Literature DB >> 32869169 |
Rajender Kumar1, Ruma Rani2, Saroj Kumar3, Khushboo Sethi2, Shikha Jain2, Kanisht Batra4, Sanjay Kumar2, B N Tripathi2.
Abstract
Trypanosoma evansi, an extracellular haemoflagellate, has a wide range of hosts receptive and susceptible to infection, in which it revealed highly inconsistent clinical effects. Drugs used for the treatment of trypanosomosis have been utilized for more than five decades and have several problems like local and systemic toxicity. In the present investigation, imatinib and sorafenib were selected as drugs as they are reported to have the potential to cause reactive oxygen species (ROS)-mediated effect in cancer cells. Both have also been reported to have potential against T. brucei, T. cruzi and Leishmania donovani. To date, imatinib and sorafenib have not evaluated for their growth inhibitory effect against T. evansi. Imatinib and sorafenib showed significant (p < 0.001) inhibition on parasite growth and multiplication with IC50 (50% inhibitory concentration) values 6.12 μM and 0.33 μM respectively against T. evansi. Both the drug molecules demonstrated for the generation of ROS in T. evansi and were found up to 65% increased level of ROS as compared with negative control in the axenic culture system. Furthermore, different concentrations of imatinib and sorafenib were found non-toxic on horse peripheral blood mononuclear cells and Vero cell lines. Also, in conclusion, our results demonstrated that imatinib- and sorafenib-induced generation of ROS contributed inhibitory effect on the growth of Trypanosoma evansi in an axenic culture system.Entities:
Keywords: Growth inhibition assay; In vitro resazurin cytotoxicity assay; ROS measurement assay; Surra; Trypanosoma evansi; Trypanosomosis
Mesh:
Substances:
Year: 2020 PMID: 32869169 DOI: 10.1007/s00436-020-06861-7
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.289